1
|
Stein Gold L, Adam DN, Albrecht L, Alonso-Llamazares J, Ferris LK, Gooderham MJ, Hong HCH, Kempers SE, Kircik LH, Lebwohl M, Loo WJ, Nahm WK, Papp KA, Stewart D, Toth DP, Zirwas M, Krupa D, Snyder S, Burnett P, Higham R, Berk DR. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: a 52-week, phase 2, open-label trial. J Am Acad Dermatol 2024:S0190-9622(24)00541-3. [PMID: 38556093 DOI: 10.1016/j.jaad.2024.03.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 03/15/2024] [Accepted: 03/19/2024] [Indexed: 04/02/2024]
Abstract
BACKGROUND Efficacy and/or safety profiles limit topical psoriasis treatments. OBJECTIVE Evaluate long-term effects of once-daily roflumilast cream 0.3% in patients with psoriasis. METHODS In this open-label phase 2 trial, adult patients (N = 332) with psoriasis who completed the phase 2b parent trial or were newly enrolled applied roflumilast once-daily for 52 weeks. Safety and effectiveness were assessed. RESULTS Overall, 244 patients (73.5%) completed the trial; 13 patients (3.9%) discontinued due to adverse events (AEs) and 3 (0.9%) due to lack of efficacy. Twelve patients (3.6%) reported treatment-related AEs; none were serious. ≥97% of patients had no irritation. No tachyphylaxis was observed with 44.8% of the patients achieving Investigator Global Assessment (IGA) Clear or Almost Clear at Week 52. LIMITATIONS Intertriginous-IGA and Psoriasis Area and Severity Index (PASI) were not evaluated in all patients. CONCLUSIONS In this long-term trial, once-daily roflumilast cream was well-tolerated and efficacious up to 64 weeks in patients in the earlier trial, suggesting it is suitable for chronic treatment, including the face and intertriginous areas.
Collapse
Affiliation(s)
| | - David N Adam
- CCA Medical Research, Probity Medical Research and Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Lorne Albrecht
- Enverus Medical Research, Surrey, British Columbia, Canada
| | | | - Laura K Ferris
- University of Pittsburgh, Department of Dermatology, Pittsburgh, Pennsylvania
| | - Melinda J Gooderham
- SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough, Ontario, Canada
| | - H Chih-Ho Hong
- Probity Medical Research and University of British Columbia, Department of Dermatology and Skin Science, Surrey, British Columbia, Canada
| | | | - Leon H Kircik
- Icahn School of Medicine at Mount Sinai, New York, New York, Indiana Medical Center, Indianapolis, Indiana, Physicians Skin Care, PLLC, Louisville, Kentucky, and Skin Sciences, PLLC, Louisville, Kentucky
| | - Mark Lebwohl
- Icahn School of Medicine at Mount Sinai, New York, New York
| | - Wei Jing Loo
- DermEffects, Probity Medical Research, and Western University, London, Ontario, Canada
| | - Walter K Nahm
- University of California, San Diego, School of Medicine, San Diego, California
| | - Kim A Papp
- Probity Medical Research and Alliance Clinical Trials, Waterloo, and University of Toronto, Toronto, Ontario, Canada
| | - Daniel Stewart
- Michigan Center for Skin Care Research, Clinton Township, Michigan
| | - Darryl P Toth
- XLR8 Medical Research, Probity Medical Research, Windsor, Ontario, Canada
| | - Matthew Zirwas
- Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley, Ohio
| | - David Krupa
- Arcutis Biotherapeutics, Inc., Westlake Village, California
| | - Scott Snyder
- Arcutis Biotherapeutics, Inc., Westlake Village, California
| | | | - Robert Higham
- Arcutis Biotherapeutics, Inc., Westlake Village, California
| | - David R Berk
- Arcutis Biotherapeutics, Inc., Westlake Village, California
| |
Collapse
|
2
|
Ludbrook VJ, Budd DC, Thorn K, Tompson D, Votta BJ, Walker L, Lee A, Chen X, Peppercorn A, Loo WJ. Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Dermatol Ther (Heidelb) 2024; 14:489-504. [PMID: 38372938 PMCID: PMC10890982 DOI: 10.1007/s13555-024-01097-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2023] [Accepted: 01/05/2024] [Indexed: 02/20/2024] Open
Abstract
INTRODUCTION Receptor-interacting protein kinase 1 (RIPK1), a key mediator of inflammation through necroptosis and proinflammatory cytokine production, may play a role in the pathogenesis of immune-mediated inflammatory diseases such as chronic plaque psoriasis. An experimental medicine study of RIPK1 inhibition with GSK2982772 immediate-release formulation at doses up to 60 mg three times daily in mild to moderate plaque psoriasis indicated that efficacy may be improved with higher trough concentrations of GSK2982772. METHODS This multicenter, randomized, double-blind, placebo-controlled, repeat-dose study (NCT04316585) assessed the efficacy, safety, pharmacokinetics, and pharmacodynamics of 960 mg GSK2982772 (once-daily modified-release formulation) in patients with moderate to severe plaque psoriasis. Twenty-nine patients were randomized 2:1 to GSK2982772 (N = 19) or placebo (N = 10) for 12 weeks. RESULTS GSK2982772 was well tolerated with trough concentrations greater than tenfold higher than the previous phase 1 study with immediate release. Despite near complete RIPK1 target engagement in blood and modest reduction in circulating inflammatory cytokines, the proportion of patients achieving 75% improvement from baseline in Psoriasis Area Severity Index score at week 12 was similar between GSK2982772 and placebo (posterior median 1.8% vs 4.9%, respectively), with an estimated median treatment difference of - 2.3%. This analysis incorporated historical placebo data through the use of an informative prior distribution on the placebo arm. Week 4 changes in skin biopsy gene expression suggested sufficient local drug exposure to elicit a pharmacodynamic response. CONCLUSION Administration of the RIPK1 inhibitor GSK2982772 to patients with moderate to severe plaque psoriasis did not translate into meaningful clinical improvements.
Collapse
Affiliation(s)
- Valerie J Ludbrook
- Clinical Pharmacology and Experimental Medicine, GSK, Gunnels Wood Rd, Stevenage, Hertfordshire, SG1 2NY, UK.
| | - David C Budd
- Medicines Research Centre, GSK, Stevenage, Hertfordshire, UK
| | - Katie Thorn
- Biostatistics, GSK, Stevenage, Hertfordshire, UK
| | - Debra Tompson
- Clinical Pharmacology Modelling and Simulation, GSK, Stevenage, Hertfordshire, UK
| | | | - Lucy Walker
- Clinical Pharmacology and Experimental Medicine, GSK, Gunnels Wood Rd, Stevenage, Hertfordshire, SG1 2NY, UK
- Global Safety, GSK, GSK House, Brentford, UK
| | - Amy Lee
- Rx Global Clinical Delivery, GSK, Mississauga, ON, Canada
| | - Xin Chen
- Rx Global Clinical Delivery, GSK, Mississauga, ON, Canada
| | | | | |
Collapse
|
3
|
Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine 2023; 57:101826. [PMID: 36816342 PMCID: PMC9932343 DOI: 10.1016/j.eclinm.2023.101826] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 12/16/2022] [Accepted: 01/04/2023] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Prurigo nodularis is a chronic skin disease characterised by intensely pruritic, hyperkeratotic nodules. Vixarelimab, a human monoclonal antibody, binds to the beta subunit of the oncostatin M receptor, inhibiting signalling of both interleukin 31 and oncostatin M, two cytokine pathways that contribute to pruritus and nodule formation in prurigo nodularis. METHODS This double-blind, placebo-controlled, phase 2a trial was done at both private and academic dermatology outpatient research clinics across the United States and Canada (n = 40). Patient eligibility criteria included age 18-75 years, physician-documented diagnosis of prurigo nodularis minimum 6 months duration of prurigo nodularis, presence of at least 10 pruritic nodules approximately 0.5-2 cm in size on at least two different anatomical locations (excluding face and scalp) and involving the extremities, and presence of normal-appearing skin between nodules; atopic dermatitis as a comorbidity was exclusionary. Patients were required to have moderate-to-severe pruritus, defined as Worst Itch-Numeric Rating Scale (WI-NRS) score ≥7 at screening and LS-mean weekly WI-NRS score ≥5 for each of the 2 consecutive weeks immediately before randomisation. Participants were randomly assigned (1:1) to receive weekly subcutaneous vixarelimab 360 mg (720 mg loading dose) or placebo using stratification factors (sex and presence of atopy) and block size 4 through the IWRS system. Stratification by atopy status was based on the reported high prevalence of atopy in this population and the potential impact of atopy in the immunopathologic process in prurigo nodularis. Patients, investigators, study sponsor, and site staff were masked to study treatment. The primary efficacy endpoint was least squares (LS)-mean percent change from baseline (PCFB) at Week 8 in weekly average Worst Itch-Numeric Rating Scale (WI-NRS) score. The primary efficacy endpoint was analysed with ANCOVA including treatment as fixed effect, with baseline WI-NRS, and randomisation stratification factor as covariates. All randomised patients who had at least 1 dose of study drug or placebo were included in the Safety Analysis Set. This trial is registered at ClinicalTrials.gov, NCT03816891. FINDINGS Of 50 patients randomised between March 11, 2019 and January 31, 2020, 23 vixarelimab recipients and 26 placebo recipients comprised the modified intent-to-treat analysis population (baseline LS-mean [SD] WI-NRS score, 8.3 [1.05]). Outcomes at Week 8 for vixarelimab versus placebo included LS-mean PCFB in WI-NRS score, -50.6% versus -29.4% (LS-mean difference [95% CI], -21.2% [-40.82, -1.60]; p = 0.03); ≥4-point reduction in WI-NRS score, 52.2% (12/23) versus 30.8% (8/26) (p = 0.11); PN-IGA score of 0 or 1, 30.4% (7/23) versus 7.7% (2/26) (p = 0.03); LS-mean PCFB in pruritus VAS score, -54.4% versus -32.6% (p = 0.03); and LS-mean PCFB sleep loss reduction (improvement), -56.3% versus -30.0% (p = 0.02). No deaths, serious TEAEs, or TEAEs leading to dose interruption were reported. The percentage of vixarelimab recipients reporting any TEAE was 91.3% (21/23) versus 76.9% (20/26) of placebo recipients; drug-related TEAEs generally were similar between the two groups (vixarelimab, 43.5% [10/23]; placebo, 38.5% [10/26]). INTERPRETATION Vixarelimab demonstrated rapid reduction of pruritus and achievement of clear/almost clear skin in one-third of the patients by Week 8. Relief of itch and clearing of skin nodules represent two important potential therapeutic advances in the management of patients suffering from the debilitating disease Prurigo Nodularis. FUNDING Kiniksa Pharmaceuticals, Ltd.
Collapse
Affiliation(s)
- Howard Sofen
- UCLA School of Medicine, Los Angeles, CA, USA
- Corresponding author. Department of Medicine/Dermatology, David Geffen UCLA School of Medicine, Los Angeles, CA, 90045, USA.
| | | | - Gil Yosipovitch
- University of Miami Miller School of Medicine, Miami, FL, USA
| | - Jonathan I. Silverberg
- George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| | - Stephen Tyring
- Department of Dermatology and Centre for Clinical Studies, University of Texas Health Science Centre, Houston, TX, USA
| | - Wei Jing Loo
- Derm Effects & Probity Medical Research, London, Ontario, Canada
| | | | - Mark Lee
- Progressive Clinical Research, San Antonio, TX, USA
| | | | | | | |
Collapse
|
4
|
Eyerich K, Loo WJ, Calimlim BM, Lee WJ, Chen SH, Sanchez CS, Lauffer F. 354 Genital involvement in patients with atopic dermatitis is associated with sexual difficulties and higher disease burden: results from a real-world multicountry cohort study (MEASURE-AD). Br J Dermatol 2023. [DOI: 10.1093/bjd/ljac140.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Abstract
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease characterized by erythematous and pruritic lesions. Genital involvement of AD is not well characterized or studied; the prevalence of genital AD and its impact on sexual function and quality of life has not been fully elucidated. To evaluate disease burden and quality of life among patients with genital involvement of AD. MEASURE-AD is a cross-sectional, non-interventional cohort study enrolling subjects from 28 countries to assess the disease burden associated with moderate-to-severe AD. Patients aged ≥12 years with a physician-confirmed diagnosis of moderate-to-severe AD who were receiving or eligible to receive systemic therapy were enrolled between December 2019 and December 2020 during routine clinic visits. Patients ≥16 years were included in this post-hoc analysis. Genital involvement was identified using the SCORing Atopic Dermatitis (SCORAD) index. The extent and severity of AD were evaluated using the Eczema Area and Severity Index (EASI), body surface area (BSA) and the validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD). Pruritus was assessed using the Worst Pruritus Numeric Rating Scale (WP-NRS). Quality of life assessments were conducted using the Dermatology Life Quality Index (DLQI)/Children’s DLQI (CDLQI). Association between burden and genital AD was analysed by applying Kruskal-Wallis and Chi-square tests to continuous and categorical variables, respectively. In the MEASURE-AD study, 1474 patients (708 females [48.0%]; 766 males [52.0%]) were enrolled with a mean (SD) age of 38.0 (16.5) years and AD duration of 23.3 (15.4) years. A total of 245 patients (16.6%) were identified as having genital AD; 1229 (83.4%) had no genital AD involvement. Patients with genital AD had significantly higher EASI (mean [SD]: 23.5 [13.7] vs. 13.1 [12.0]) and WP-NRS (6.4 [2.6] vs. 5.1 [3.1]) scores (P < 0.0001 for both), a greater number of AD regions affected (three other regions affected: 94.7% vs. 60.5%; P < 0.0001), greater body surface area involvement (mean [SD]: 40.9% [24.7] vs. 21.5% [20.72]; P < 0.0001), and more severe disease (vIGA-AD score of 4: 31.8% vs. 17.6%; P < 0.0001) than patients without genital AD. Patients with genital AD had greater impairment in quality of life compared with those without genital involvement (DLQI mean [SD]: 13.9 [7.4] vs. 10.1 [7.7]; P < 0.0001). Specifically, more patients with genital AD experienced sexual difficulties than those without genital AD (DLQI sexual difficulties, a lot/very much: 37.8% vs. 18.4%; P < 0.0001). Patients with genital AD experienced a higher disease burden and greater impairment of quality of life with a considerable impact on sexual function compared with patients without genital involvement. Healthcare providers should proactively inquire about genital AD symptoms as some patients may be hesitant to raise the topic out of embarrassment or fear of judgment. Effective treatment is important for mitigating the multidimensional burden of AD; the burden of genital AD should be considered during treatment decision-making discussions between patients and healthcare providers.
Collapse
Affiliation(s)
- Kilian Eyerich
- Department of Dermatology, Faculty of Medicine, Albert-Ludwigs-Universität Freiburg , Freiburg , Germany
- Karolinska Institutet and Karolinska University Hospital , Stockholm , Sweden
| | | | | | | | | | | | - Felix Lauffer
- Department of Dermatology and Allergy, Technical University of Munich , Munich , Germany
| |
Collapse
|
5
|
Loo WJ, Turchin I, Prajapati VH, Gooderham MJ, Grewal P, Hong CH, Sauder M, Vender RB, Maari C, Papp KA. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. J Cutan Med Surg 2023; 27:3S-24S. [PMID: 36519621 DOI: 10.1177/12034754221141680] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Cytokines in the interleukin (IL)-23/IL-17 axis are central to psoriasis pathogenesis. Janus kinase (JAK) signal transducer and activator of transcription (STAT) regulates intracellular signalling of several cytokines (including IL-12, 23, 22, 6, 17, and interferon (IFN)-γ) in the IL-23/IL-17 axis, and, as a result, has become a therapeutic target for psoriasis treatment. Although several JAK1-3 inhibitors, with varying degrees of selectivity, have been developed for immune-mediated inflammatory diseases, use in psoriasis is limited by a low therapeutic index as anticipated by signals from other disease indications. More selective inhibition of the JAK family is an area of interest. Specifically, selective tyrosine kinase (TYK)2 inhibition suppresses IL-23/IL-17 axis signalling, and at therapeutic doses, has a favorable safety profile compared to therapeutic doses of JAK1-3 inhibitors. Phase III efficacy and safety data for the selective allosteric TYK2-inhibitor, deucravacitinib, in adult patients with moderate-to-severe plaque psoriasis is promising. Furthermore, phase II clinical trials for ropsacitinib (PF-06826647), a selective TYK2 inhibitor, and brepocitinib (PF-06700841), a JAK1/TYK2 inhibitor, have also demonstrated efficacy and an acceptable safety profile in adult patients with moderate-to-severe plaque psoriasis. Other novel TYK2 allosteric inhibitors, NDI-034858 and ESK-001, are currently being investigated in adult patients with plaque psoriasis. This article reviews the details of the JAK-STAT pathway in psoriasis pathophysiology, the rationale for selective targeting of JAKs in the treatment of psoriasis, and provides clinical perspective on clinical trial data for JAK and TYK2 inhibitors.
Collapse
Affiliation(s)
- Wei Jing Loo
- DermEffects, London, Ontario, Canada.,468790 Probity Medical Research Inc., Waterloo, ON, Canada
| | - Irina Turchin
- 468790 Probity Medical Research Inc., Waterloo, ON, Canada.,Brunswick Dermatology Center, Fredericton, NB, Canada.,Department of Medicine, Dalhousie University, Halifax, NS, Canada
| | - Vimal H Prajapati
- 70401 Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.,Section of Community Pediatrics, Department of Pediatrics, Calgary, AB, Canada.,Section of Pediatric Rheumatology, Department of Pediatrics, Calgary, AB, Canada.,Skin Health & Wellness Centre, Calgary, AB, Canada.,Dermatology Research Institute, Calgary, AB, Canada.,468790 Probity Medical Research, Calgary, AB, Canada
| | - Melinda J Gooderham
- 468790 Probity Medical Research Inc., Waterloo, ON, Canada.,SKiN Centre for Dermatology, Peterborough, ON, Canada
| | - Parbeer Grewal
- Rejuvenation Dermatology, Edmonton, AB, Canada.,Division of Dermatology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
| | - Chih-Ho Hong
- 468790 Probity Medical Research Inc., Waterloo, ON, Canada.,Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.,Dr. Chih-Ho Hong Medical Inc., Surrey, BC, Canada
| | - Maxwell Sauder
- 468790 Probity Medical Research Inc., Waterloo, ON, Canada.,Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
| | - Ronald B Vender
- Dermatrials Research Inc. & Venderm Innovations in Psoriasis, Hamilton, ON, Canada.,Division of Dermatology, Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Catherine Maari
- Innovaderm Research Inc, Montreal, QC, Canada.,10051 Department of Medicine, Division of Dermatology, Montreal University Hospital Center, Montreal, QC, Canada
| | - Kim A Papp
- 468790 Probity Medical Research Inc., Waterloo, ON, Canada.,K Papp Clinical Research, Waterloo, ON, Canada
| |
Collapse
|
6
|
Affiliation(s)
- J Chia
- Schulich School of Medicine, University of Western Ontario, London, Ontario, Canada.
| | | | | |
Collapse
|
7
|
Abstract
Background: Psoriasis and multiple sclerosis (MS) are both autoimmune T cell-mediated diseases. Some case series have suggested an association. Objective: To investigate the potential relationship between psoriasis and MS based on a systematic review of the literature. Methods: Medline, Cochrane Library, and EMBASE searches were performed. Results: T-helper 17 cells are involved in the pathogenesis of both psoriasis and MS. Both conditions have been associated with interleukin-23 receptor (IL23R) polymorphisms. Studies have reported psoriasis in 0.41 to 7.7% of individuals with MS. A higher rate of psoriasis compared to controls was noted in a few small MS cohorts, but the number of cases was too small to draw any firm conclusions. In two studies, including a large Canadian study of 5,031 patients with MS, there was no increased prevalence of psoriasis in patients over the control population. Family members of individuals with MS do not appear to be at increased risk for psoriasis in these studies. Psoriasis has developed during treatment for MS, and MS has developed during treatment for psoriasis. Conclusion: Although there are some common genetic linkages in psoriasis and MS, psoriasis does not appear to be more common in patients with MS or their relatives.
Collapse
Affiliation(s)
- Tiffany Kwok
- From the Schulich School of Medicine, University of Western Ontario, London, ON, and St. Joseph's Health Care, London, ON
| | - Wei Jing Loo
- From the Schulich School of Medicine, University of Western Ontario, London, ON, and St. Joseph's Health Care, London, ON
| | - Lyn Guenther
- From the Schulich School of Medicine, University of Western Ontario, London, ON, and St. Joseph's Health Care, London, ON
| |
Collapse
|
8
|
|
9
|
Abstract
BACKGROUND Cigarette smoking causes accelerated facial wrinkling and predisposes to chronic obstructive pulmonary disease (COPD). However, it has long been recognised that there is a subgroup of susceptible smokers who are at increased risk of developing airflow obstruction. We have tested the hypothesis that there is a common susceptibility for the development of COPD and facial wrinkling in cigarette smokers. METHODS One hundred and forty nine current and ex-smokers were recruited from a family based study of COPD genetics, 68 (45.6%) of whom fulfilled the definition of COPD. 124 (83.2%) had no or minor facial wrinkling (Daniell <IV) and 25 (16.8%) were wrinkled (Daniell score >/=IV). Generalised estimating equations were used to adjust for familial correlations between related individuals and the potential confounding effects of age and pack years smoked. RESULTS Forced expiratory volume in 1 second (FEV(1)) was significantly lower in those with wrinkles than in those without (mean difference in FEV(1) % predicted -13.7%, 95% CI -27.5 to 0.0, p = 0.05) and facial wrinkling was associated with a substantially increased risk of COPD (adjusted OR 5.0, 95% CI 1.3 to 18.5, p<0.02). The Daniell score correlated with the extent of emphysema on the CT scan (p<0.05) and facial wrinkling was also associated with a greater risk of more extensive emphysema (adjusted OR 3.0, 95% CI 1.0 to 9.3, p = 0.05). CONCLUSION Facial wrinkling is associated with COPD in smokers, and both disease processes may share a common susceptibility. Facial wrinkling in smokers may therefore be a biomarker of susceptibility to COPD.
Collapse
Affiliation(s)
- B D Patel
- Department of Public Health and Primary Care, University of Cambridge, UK.
| | | | | | | | | | | | | |
Collapse
|
10
|
Affiliation(s)
- W J Loo
- Department of Dermatology, Addenbrooke's NHS Trust, Cambridge, UK.
| | | |
Collapse
|
11
|
|
12
|
Abstract
This case illustrates the rare association between hidradenitis suppurativa (HS) and Dowling-Degos disease (DDD). Furthermore the association of HS, DDD and multiple epidermal cysts has not to our knowledge been described before, but their coexistence in the same patient is likely to reflect the same follicular anomaly. It is possible that a single underlying defect of follicular proliferation may account for the coexistence of these conditions.
Collapse
Affiliation(s)
- W J Loo
- Department of Dermatology, Addenbrooke's NHS Trust, Cambridge, UK.
| | | | | |
Collapse
|
13
|
Burrows N, Norris P, Loo WJ. Clinical management where medicine meets management. More than skin deep. Health Serv J 2004; 114:24-5. [PMID: 15554042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
Modernisation has brought down outpatient waits and did-not-attends at Addenbrooke Hospital's dermatology department. A 360-degree review of services has led to continuous service Improvement. GPs and hospital nurses have received specialist training, freeing up consultant time and enabling more consultants to be seen.
Collapse
|
14
|
Affiliation(s)
- W J Loo
- Department of Dermatology, Addenbrooke's NHS Trust, Cambridge, UK. wjloo@hotmailcom
| | | | | |
Collapse
|
15
|
Abstract
We report the case of a patient with atypical Sweet's syndrome characterized by an annular erythema that showed consumption of elastic fibres by giant cells and histiocytes. Although the lesions were found on sun-exposed sites and the first biopsy demonstrated extensive elastophagocytosis, our patient did not have photodamaged skin clinically. A repeat biopsy 5 weeks later demonstrated an abundant collection of neutrophils supporting the diagnosis of Sweet's syndrome. To our knowledge, an elastolytic granulomatous reaction pattern has not been previously reported in Sweet's syndrome.
Collapse
Affiliation(s)
- W J Loo
- Department of Dermatology, Addenbrookes' NHS Trust, Cambridge, UK.
| | | | | |
Collapse
|
16
|
Abstract
Senescence of the skin immunological system may explain why the elderly population has an increased susceptibility to certain autoimmune skin disorders. These disorders are characterised by the production of either antibodies that react with host tissue or immune effector T cells that are autoreactive. Bullous pemphigoid is the most common autoimmune blistering disease in the elderly. Although oral corticosteroids are the best established therapy, high-potency topical corticosteroids are very useful as initial treatment and, in the elderly, should be used instead of oral prednisolone wherever possible. Pemphigus is a chronic blistering disease of which there are two main subtypes: vulgaris and foliaceous. Paraneoplastic pemphigus is a unique clinical, histological and immunologically distinct autoimmune mucocutaneous disease which tends to be relentlessly progressive. Lichen sclerosus presents specific complications and a small but definite increased risk of squamous cell carcinoma in elderly patients. It is important to be aware of practical issues such as the difficulty in applying topical corticosteroids, the mainstay treatment of this condition. Dermatomyositis is an autoimmune systemic disorder where the skin and muscles are the most commonly affected organs. Tumour-associated disease occurs more commonly in elderly patients and has a poorer prognosis. Management of the disease includes sunscreens, topical or systemic corticosteroids, antimalarials, oral immunosuppressants or intravenous immunoglobulins. It is important to bear in mind that old age modifies the management of skin diseases because of physical and social circumstances as well as the unwanted adverse effects of medications. Polypharmacy results in an increased risk of drug interactions and, therefore, drug regimens need to be kept as simple as possible. Drug-induced autoimmune skin eruptions are common amongst the elderly and usually resolve when the offending drug is discontinued.
Collapse
Affiliation(s)
- Wei Jing Loo
- Department of Dermatology, Addenbrooke's NHS Trust, Cambridge, UK.
| | | |
Collapse
|
17
|
|
18
|
Affiliation(s)
- W J Loo
- Department of Dermatology, Addenbrooke's NHS Trust, Cambridge, London, UK.
| | | | | | | |
Collapse
|
19
|
|
20
|
Abstract
BACKGROUND An illustrated version of the Dermatology Life Quality Index (DLQI) was developed in order to improve the ease with which this standard questionnaire is answered. OBJECTIVES To compare the illustrated version with the text-only version of the DLQI. METHODS The two versions were administered to 206 patients attending Dermatology outpatient clinics. The time taken to complete either the illustrated or the text-only version was noted in 52 additional patients. RESULTS One hundred and ninety-one of 206 patients completed both questionnaires satisfactorily. Their mean DLQI scores were 6.4 (median 4.0, lower quartile 1.0, upper quartile 11.0) for the illustrated version and 6.3 (median 4.0, lower quartile 1.0, upper quartile 10.0) for the text-only version. For the 98 patients who answered the illustrated version first, the mean DLQI scores were 6.9 (median 4.0, lower quartile 1.9, upper quartile 11.9) for the illustrated version and 6.4 (median 4.0, lower quartile 1.8, upper quartile 11.0) for the text-only version. For the 93 patients who answered the text-only version first, the mean DLQI scores were 5.9 (median 4.0, lower quartile 1.7, upper quartile 10.2) for the illustrated version and 6.2 (median 5.0, lower quartile 0.5, upper quartile 9.5) for the text-only version. The median time taken to complete the text-only version was 124 s (mean +/- SD 126 +/- 65, n = 27) and 88 s (mean +/- SD 101 +/- 52, n = 25) for the illustrated version (P = 0.08). There was a very close correlation (r = 0.98) between the scores of the text-only and the illustrated versions; 82.2% of patients either scored the same or had a DLQI score difference of only 1. One hundred and seven (59.8%) patients preferred using the illustrated version and 66 (36.9%) preferred the text-only version. One hundred and four (57.5%) found the illustrated version easier to use. CONCLUSIONS The illustrated version was superior to the text-only version in terms of patient preference and ease of use, but it was not possible to demonstrate exact equivalence between the two versions.
Collapse
Affiliation(s)
- W J Loo
- Department of Dermatology, Addenbrooke's NHS Trust, Hills Road, Cambridge CB2 2QQ, UK.
| | | | | | | |
Collapse
|
21
|
|
22
|
Abstract
Hirsutism has a significant impact on the quality of life of affected patients. We report a prospective study of 45 hirsute females attending a laser clinic. Of these, 15 patients completed a pair of modified dermatology life quality index (DLQI) questionnaires, immediately before and at varying intervals (up to 6 months) after laser treatment. The mean DLQI score before treatment was 12.8 (median = 9.0, SD = 8.5). The mean DLQI score at 1-2 months was 7.0 (median = 2.5, SD = 10.0, P = 0.06), at 2-4 months it was 9.2 (median = 10.0, SD = 10.0, P = 0.48) and at 4-6 months it was 11.5 (median = 10.5, SD = 8.0, P = 0.88). There was a major improvement in DLQI score at 1-2 months but longer-term benefit was not observed. In a separate questionnaire, hirsute females (n = 45) reported a high level of patient satisfaction (71.1%) and willingness to have further treatment (77.8%) despite the fact that 97.1% had unwanted hair back at pretreatment levels at 6 months.
Collapse
Affiliation(s)
- W J Loo
- Department of Dermatology, Addenbrooke's NHS Trust, Cambridge, UK.
| | | |
Collapse
|
23
|
Abstract
We report two cases of keratosis follicularis spinulosa decalvans in a Caucasian family involving a 28-year-old woman and her mother. This is an unusual family in that no male relatives are similarly affected. Secondly, both patients have no significant eye changes but quite extensive scarring alopecia. To the best of our knowledge this is the second reported family in the UK.
Collapse
Affiliation(s)
- N P Khumalo
- Department of Dermatology, Groote Schuur Hospital, Capetown, South Africa
| | | | | | | | | | | |
Collapse
|
24
|
Abstract
The use of lasers for the treatment of cutaneous vascular disorders has expanded rapidly since its inception in the early 1960s. The flashlamp-pumped pulsed tunable dye laser (PDL), which is the best laser system for the treatment of port-wine stains (PWS), is based on the premise of selective photothermolysis. Recent literature demonstrates enhanced selective photothermolysis by modifying the PDL to include a longer pulse width, a longer wavelength and higher energy fluences through the use of dynamic cooling. Multiple pulse laser irradiation, a new innovative method, shows promising preliminary results in eradicating hypertrophic PWS. In the treatment of capillary haemangiomas, previous uncontrolled studies suggest benefit with early PDL therapy but a recent randomised controlled trial does not support this claim. Mixed haemangiomas respond poorly to PDL treatment, uncomplicated tumours are best left to involute spontaneously whilst life/organ-threatening lesions require early active intervention. The efficacy of lasers in the treatment of telangiectatic leg veins (TLV) remains controversial. The literature revealed many conflicting claims. Larger and properly controlled studies are necessary to better define the role of lasers in the treatment of TLV.
Collapse
Affiliation(s)
- W J Loo
- Department of Dermatology, Addenbrooke's NHS Trust, Cambridge, UK
| | | |
Collapse
|
25
|
Loo WJ, Dean D, Wojnarowska F. A severe persistent case of recurrent pemphigoid gestationis successfully treated with minocycline and nicotinamide. Clin Exp Dermatol 2001; 26:726-7. [PMID: 11722465 DOI: 10.1046/j.1365-2230.2001.00926-2.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
26
|
Abstract
We present a retrospective analysis of patients with bullous pemphigoid (BP) treated with minocycline in the Department of Dermatology, Churchill Hospital, Oxford between July 1986 and May 2000. More than 200 patients with BP were seen in clinic during the review period. Of these, 22 patients were treated with minocycline, mostly as adjuvant therapy. The response to treatment was assessed by clinical improvement and whether the dose of concurrent immunosuppressive drugs was subsequently reduced. A major response was seen in six patients, a minor response in 11 and no response was seen in five patients. Minocycline was discontinued in four patients because of the occurrence of side-effects. Overall analysis revealed marked clinical benefits of minocycline in BP. However, this is a non-placebo controlled study and should now be followed by a prospective double-blind controlled clinical trial.
Collapse
Affiliation(s)
- W J Loo
- Department of Dermatology, The Churchill, Oxford Radcliffe Hospital, Headington, Oxford, UK.
| | | | | |
Collapse
|
27
|
Loo WJ, Dawber RP. Nail dystrophy in association with polydactyly and benign familial hypercalcemia. Clin Exp Dermatol 2001; 26:102-3. [PMID: 11260193 DOI: 10.1046/j.1365-2230.2001.00770-4.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
28
|
|
29
|
|